These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 33176437)

  • 41. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
    Butler J; Filippatos G; Siddiqi TJ; Ferreira JP; Brueckmann M; Bocchi E; Böhm M; Chopra VK; Giannetti N; Iwata T; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Rauch-Kröhnert U; Shah SJ; Senni M; Sumin M; Verma S; Zhang J; Pocock SJ; Zannad F; Packer M; Anker SD
    Circulation; 2022 Oct; 146(14):1046-1055. PubMed ID: 36098051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.
    Vetrovsky T; Siranec M; Frybova T; Gant I; Svobodova I; Linhart A; Parenica J; Miklikova M; Sujakova L; Pospisil D; Pelouch R; Odrazkova D; Parizek P; Precek J; Hutyra M; Taborsky M; Vesely J; Griva M; Semerad M; Bunc V; Hrabcova K; Vojkuvkova A; Svoboda M; Belohlavek J;
    Circulation; 2024 Jan; 149(3):177-188. PubMed ID: 37955615
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
    Greenberg BH; Chou W; Saikali KG; Escandón R; Lee JH; Chen MM; Treshkur T; Megreladze I; Wasserman SM; Eisenberg P; Malik FI; Wolff AA; Shaburishvili T
    JACC Heart Fail; 2015 Jan; 3(1):22-29. PubMed ID: 25453536
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.
    Filippatos G; Maggioni AP; Lam CSP; Pieske-Kraigher E; Butler J; Spertus J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Bamber L; Gheorghiade M; Pieske B
    Eur J Heart Fail; 2017 Jun; 19(6):782-791. PubMed ID: 28586537
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.
    Mamidi R; Li J; Gresham KS; Verma S; Doh CY; Li A; Lal S; Dos Remedios CG; Stelzer JE
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29030372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
    Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
    JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Eligibility for omecamtiv mecarbil in a real-world heart failure population: Data from the Swedish Heart Failure Registry.
    Lindberg F; Øigaard N; Metra M; Rosano GMC; Dahlström U; Mol P; Hage C; Lund LH; Savarese G
    PLoS One; 2024; 19(5):e0303348. PubMed ID: 38787867
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extended-Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Nanayakkara S; Byrne M; Mak V; Carter K; Dean E; Kaye DM
    J Am Heart Assoc; 2020 Jul; 9(13):e015026. PubMed ID: 32552264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.
    Metra M; Pagnesi M; Claggett BL; Díaz R; Felker GM; McMurray JJV; Solomon SD; Bonderman D; Fang JC; Fonseca C; Goncalvesova E; Howlett JG; Li J; O'Meara E; Miao ZM; Abbasi SA; Heitner SB; Kupfer S; Malik FI; Teerlink JR
    Eur Heart J; 2022 Dec; 43(48):5006-5016. PubMed ID: 35675469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
    Bonnet D; Berger F; Jokinen E; Kantor PF; Daubeney PEF
    J Am Coll Cardiol; 2017 Sep; 70(10):1262-1272. PubMed ID: 28859790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation.
    El Oumeiri B; van de Borne P; Hubesch G; Herpain A; Annoni F; Jespers P; Stefanidis C; Mc Entee K; Vanden Eynden F
    Physiol Rep; 2021 Aug; 9(16):e14988. PubMed ID: 34405966
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis.
    Alqatati F; Elbahnasawy M; Bugazia S; Ragab KM; Elsnhory AB; Shehata M; Elsayed SM; Fathy MA; Nourelden AZ
    Indian Heart J; 2022; 74(3):155-162. PubMed ID: 35301008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction.
    Chen PW; Trivedi A; Lee E; Dutta S; Ahamadi M
    J Cardiovasc Pharmacol; 2022 Apr; 79(4):539-548. PubMed ID: 34983909
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.
    Ambrosy AP; Khan H; Udelson JE; Mentz RJ; Chioncel O; Greene SJ; Vaduganathan M; Subacuis HP; Konstam MA; Swedberg K; Zannad F; Maggioni AP; Gheorghiade M; Butler J
    Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27140204
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.
    Selvaraj S; Claggett B; Shah SJ; Anand IS; Rouleau JL; Desai AS; Lewis EF; Vaduganathan M; Wang SY; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2019 Jul; 12(7):e006125. PubMed ID: 31220936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.
    Van Tassell BW; Trankle CR; Canada JM; Carbone S; Buckley L; Kadariya D; Del Buono MG; Billingsley H; Wohlford G; Viscusi M; Oddi-Erdle C; Abouzaki NA; Dixon D; Biondi-Zoccai G; Arena R; Abbate A
    Circ Heart Fail; 2018 Aug; 11(8):e005036. PubMed ID: 30354558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rationale and Design of the VITALITY-HFpEF Trial.
    Butler J; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; Wu Y; Carvalho F; Bamber L; Blaustein RO; Roessig L; Armstrong PW
    Circ Heart Fail; 2019 May; 12(5):e005998. PubMed ID: 31096775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The energy-saving effect of a new myosin activator, omecamtiv mecarbil, on LV mechanoenergetics in rat hearts with blood-perfused isovolumic contraction model.
    Obata K; Morita H; Takaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Sep; 392(9):1065-1070. PubMed ID: 31267148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
    Bernier TD; Buckley LF
    J Cardiovasc Pharmacol; 2021 Jan; 77(1):4-10. PubMed ID: 33165138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.